Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do-Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li-Tzong Chen, Masayuki Kitano, Choong-kun Lee, Jin Won Kim, Ming-Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen-Shi Chen, Piotr Potemski, Howard A Burris, Vikas Ostwal, Suebpong Tanasanvimon, Chigusa Morizane, Renata E Zaucha, Mairéad G McNamara, Antonio Avallone, Juan E Cundom, Valeriy Breder, Benjamin Tan, Satoshi Shimizu, David Tougeron, Ludovic Evesque, Mila Petrova, David B Zhen, Roopinder Gillmore, Vineet Govinda Gupta, Farshid Dayyani, Joon Oh Park, Gary L Buchschacher, Felipe Rey, Hyosung Kim, Julie Wang, Claire Morgan, Nana Rokutanda, Magdalena Żotkiewicz, Arndt Vogel, Juan W Valle

Open source

DOI: 10.1016/s2468-1253(24)00095-5
Published: 2024-08
Container: The Lancet Gastroenterology & Hepatology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-24-00095-5,
  title = {Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study},
  author = {Do-Youn Oh and Aiwu Ruth He and Mohamed Bouattour and Takuji Okusaka and Shukui Qin and Li-Tzong Chen and Masayuki Kitano and Choong-kun Lee and Jin Won Kim and Ming-Huang Chen and Thatthan Suksombooncharoen and Masafumi Ikeda and Myung Ah Lee and Jen-Shi Chen and Piotr Potemski and Howard A Burris and Vikas Ostwal and Suebpong Tanasanvimon and Chigusa Morizane and Renata E Zaucha and Mairéad G McNamara and Antonio Avallone and Juan E Cundom and Valeriy Breder and Benjamin Tan and Satoshi Shimizu and David Tougeron and Ludovic Evesque and Mila Petrova and David B Zhen and Roopinder Gillmore and Vineet Govinda Gupta and Farshid Dayyani and Joon Oh Park and Gary L Buchschacher and Felipe Rey and Hyosung Kim and Julie Wang and Claire Morgan and Nana Rokutanda and Magdalena Żotkiewicz and Arndt Vogel and Juan W Valle},
  year = {2024},
  journal = {The Lancet Gastroenterology \&amp; Hepatology},
  doi = {10.1016/s2468-1253(24)00095-5},
  url = {https://doi.org/10.1016/s2468-1253(24)00095-5}
}

RIS

TY  - JOUR
TI  - Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
AU  - Do-Youn Oh
AU  - Aiwu Ruth He
AU  - Mohamed Bouattour
AU  - Takuji Okusaka
AU  - Shukui Qin
AU  - Li-Tzong Chen
AU  - Masayuki Kitano
AU  - Choong-kun Lee
AU  - Jin Won Kim
AU  - Ming-Huang Chen
AU  - Thatthan Suksombooncharoen
AU  - Masafumi Ikeda
AU  - Myung Ah Lee
AU  - Jen-Shi Chen
AU  - Piotr Potemski
AU  - Howard A Burris
AU  - Vikas Ostwal
AU  - Suebpong Tanasanvimon
AU  - Chigusa Morizane
AU  - Renata E Zaucha
AU  - Mairéad G McNamara
AU  - Antonio Avallone
AU  - Juan E Cundom
AU  - Valeriy Breder
AU  - Benjamin Tan
AU  - Satoshi Shimizu
AU  - David Tougeron
AU  - Ludovic Evesque
AU  - Mila Petrova
AU  - David B Zhen
AU  - Roopinder Gillmore
AU  - Vineet Govinda Gupta
AU  - Farshid Dayyani
AU  - Joon Oh Park
AU  - Gary L Buchschacher
AU  - Felipe Rey
AU  - Hyosung Kim
AU  - Julie Wang
AU  - Claire Morgan
AU  - Nana Rokutanda
AU  - Magdalena Żotkiewicz
AU  - Arndt Vogel
AU  - Juan W Valle
PY  - 2024
JO  - The Lancet Gastroenterology &amp; Hepatology
DO  - 10.1016/s2468-1253(24)00095-5
UR  - https://doi.org/10.1016/s2468-1253(24)00095-5
ER  -

APA

Oh, D., He, A. R., Bouattour, M., Okusaka, T., Qin, S., Chen, L., Kitano, M., Lee, C., Kim, J. W., Chen, M., Suksombooncharoen, T., Ikeda, M., Lee, M. A., Chen, J., Potemski, P., Burris, H. A., Ostwal, V., Tanasanvimon, S., Morizane, C., Zaucha, R. E., McNamara, M. G., Avallone, A., Cundom, J. E., Breder, V., Tan, B., Shimizu, S., Tougeron, D., Evesque, L., Petrova, M., Zhen, D. B., Gillmore, R., Gupta, V. G., Dayyani, F., Park, J. O., Buchschacher, G. L., Rey, F., Kim, H., Wang, J., Morgan, C., Rokutanda, N., Żotkiewicz, M., Vogel, A., & Valle, J. W. (2024). Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(24)00095-5

Source records

crossref · retrieved 2026-09-26T02:33:07.891Z